SIRIUS Cost Data Suggests Higher Inpatient Payment Level For Eluting Stents

Cost-effectiveness data collected by Johnson & Johnson/Cordis from trials of its Cypher sirolimus-eluting coronary stent will justify assigning the device to a new diagnosis-related group (DRG) in time for the expected 2003 U.S. launch, according to Cordis